Floatz logo

Pirfenidone

Prevention

Fujian Medical University Union HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Prevention cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Mazandaran University of Medical Sciences
Phase 2/3B
Alpha-Interferon
Peking University People's Hospital
N/AD
CANDESARTAN
Samsung Medical Center
N/AD
Acetylsalicylic Acid
Muhammad Hassan
D

Same molecule, other indications

Pirfenidone is also rated in:

idiopathic pulmonary fibrosisDormant
A
Indicative ·
80 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
66 / 100
View asset →
fibrotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →